"Empagliflozin significantly reduced CI-AKI incidence in PCI patients by enhancing renal function markers, including eGFR and ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

Empagliflozin users had 741 events compared to 712 in the DPP4i group, corresponding to a non-significant HR of 1.04. For DR progression, empagliflozin users experienced fewer events (158) than ...

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

Phase 2 trial findings support empagliflozin use in patients without diabetes for calcium and uric acid stone prevention. Empagliflozin use can reduce the risk of calcium and uric acid kidney stones ...

Eli Lilly and Boehringer Ingelheim's blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food and Drug Administration (FDA) for a wider range of heart failure ...

First-line empagliflozin, taken once daily for 3 months, leads to a significant reduction in weight, body mass index (BMI), and waist circumference in patients with prediabetes and diabetes.

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

Compared with people who had type 2 diabetes treated with empagliflozin (Jardiance), peers on canagliflozin (Invokana; HR 0.98, 95% CI 0.91-1.05) or dapagliflozin (Farxiga; HR 0.95, 95% CI 0.89-1. ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally ...